Efficacy and safety of pancreatic juice cytology by usingsynthetic secretin in the diagnosis of pancreatic ductaladenocarcinoma and IPMC

Phase 2

Recruiting

• Conditions: Pancreatic cancer or IPM

• Registration Number: JPRN-jRCTs061180043
• Lead Sponsor: Isomoto Hajime

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 420

Inclusion Criteria

1. Patient provided informed consent at over 20 years old
2. Patients suspected of pancreatic cancer by image examination, or patients with IPMN which is classified as high risk stigmata or worrisome features by international consensus guidelines.

Exclusion Criteria

1) Patients with hypersensitivity to secretin or other ingredients (excipients: cysteine hydrochloride and Mannitol).
2) Patients within 2 weeks after remission from acute pancreatitis or acute exacerbations of chronic pancreatitis.
3) A pregnant or lactating woman.
4) Patients who received other research drugs or investigational drugs within 3 months prior to the start of administration of the study drug.
5) Patients whom the research responsible doctor judged inappropriate.

Study & Design

• Study Type: Interventional
• Study Design: Not specified